Bosma arhinia microphthalmia syndrome

From WikiMD's Medical Encyclopedia


Bosma arhinia microphthalmia syndrome
Synonyms BAMS
Pronounce N/A
Specialty N/A
Symptoms Arhinia, microphthalmia, hypogonadotropic hypogonadism, anosmia
Complications N/A
Onset Congenital
Duration Lifelong
Types N/A
Causes Genetic mutation
Risks Family history
Diagnosis Clinical examination, genetic testing
Differential diagnosis Kallmann syndrome, CHARGE syndrome
Prevention N/A
Treatment Symptomatic treatment, hormone replacement therapy
Medication N/A
Prognosis N/A
Frequency Extremely rare
Deaths N/A


Bosma Arhinia Microphthalmia Syndrome Bosma Arhinia Microphthalmia Syndrome (BAMS) is a rare genetic disorder characterized by the absence of the nose (arhinia) and abnormalities of the eyes, particularly microphthalmia, where one or both eyes are abnormally small. This condition is extremely rare, with only a few cases reported in the medical literature.

Clinical Features[edit]

Individuals with Bosma Arhinia Microphthalmia Syndrome typically present with the following features:

  • Arhinia: Complete or partial absence of the external nose and nasal passages.
  • Microphthalmia: One or both eyes are underdeveloped, leading to vision impairment.
  • Midline Facial Defects: Other midline facial anomalies may be present, such as cleft lip or palate.
  • Hypogonadotropic Hypogonadism: A condition affecting the production of hormones that direct sexual development, leading to delayed or absent puberty.

Genetic Basis[edit]

BAMS is caused by mutations in the SMCHD1 gene, which plays a role in chromatin remodeling and gene expression regulation. The inheritance pattern of BAMS is autosomal dominant, meaning a single copy of the mutated gene can cause the disorder.

Diagnosis[edit]

Diagnosis of Bosma Arhinia Microphthalmia Syndrome is based on clinical evaluation, identification of characteristic physical features, and genetic testing to confirm mutations in the SMCHD1 gene.

Management[edit]

Management of BAMS is symptomatic and supportive, involving a multidisciplinary team approach:

Prognosis[edit]

The prognosis for individuals with Bosma Arhinia Microphthalmia Syndrome varies depending on the severity of symptoms and associated complications. Early intervention and comprehensive care can improve quality of life.

Research and Future Directions[edit]

Research into the genetic and molecular mechanisms underlying BAMS is ongoing, with the aim of developing targeted therapies and improving diagnostic techniques. Advances in genetic testing and personalized medicine hold promise for better management of this rare condition.

See Also[edit]

References[edit]

External Links[edit]

NIH genetic and rare disease info[edit]

Bosma arhinia microphthalmia syndrome is a rare disease.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.